Social Media

Lantheus is thrilled to have its late-stage clinical PET ligand for hashtagAlzheimersDisease diagnosis and treatment recognized as winner of the “Best New Imaging Technology Solution” award in the 8th annual MedTech Breakthrough Awards! Our second-generation F18-labeled PET imaging agent, currently being used as a biomarker in over 90 active academic and industry late-stage clinical trials worldwide, was selected out of thousands of nominations for its ability to detect aberrant tau protein, specifically in the form of neurofibrillary tangles, within the brains of patients known or suspected to have Alzheimer’s disease. We are honored to receive this award and to hashtagGoFurther for patients with Alzheimer’s. hashtagFindFightFollow

May 9, 2024

Read on LinkedIn

Receive Email Alerts

Media Contact

Melissa Downs

Senior Director, Corporate Communications
646-975-2533

media@lantheus.com

Investors

Mark Kinarney

Vice President, Investor Relations
978-671-8842

ir@lantheus.com